STOCKS TELEGRAPH

Tag: T2 Biosystems stock

  • Q2 Results Spark Post-Market Rally For T2 Biosystems (TTOO) Shares

    Q2 Results Spark Post-Market Rally For T2 Biosystems (TTOO) Shares

    On Monday, T2 Biosystems, Inc. (NASDAQ: TTOO) shares experienced a significant increase on the US stock market following the post-market disclosure of its second-quarter 2024 results. In the extended trading session, TTOO stock value increased 22.78% to $5.82. That followed a regular-session fall of 6.88%, where shares finished at $4.74.

    How Well T2 Biosystems Performed?

    In line with the same time last year, T2 Biosystems (TTOO) reported total sales of $2.0 million. The T2Bacteria and T2Resistance panels had robust sales, which contributed to a notable 27% rise in the company’s sepsis test revenue. Remaining at $9.2 million, or $0.66 per share, was the quarter’s net loss; for the previous year, it was $6.3 million, or $7.84 per share.

    Strategic Initiatives and Expansion

    Looking ahead, T2 Biosystems anticipates further growth in sepsis-related revenue. This expectation is bolstered by the recent FDA clearance of an expanded T2Bacteria Panel, which now includes the detection of Acinetobacter baumannii. The company also foresees potential U.S. distribution partnerships with a major healthcare company and has recently secured international distribution agreements in five new countries.

    Additionally, the upcoming launch of the T2Lyme Panel as a Laboratory Developed Test (LDT) in the third quarter of 2024 presents another significant growth opportunity.

    International Expansion and Partnership

    T2 Biosystems announced separately that a territory-exclusive distribution arrangement for Indonesia and Malaysia had been signed. The T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel shall all be marketed by the recently designated distributor in accordance with this agreement.

    This agreement signifies continued momentum in T2 Biosystems’ international commercial expansion, particularly in the Asia Pacific region, following recent market entries in Hong Kong and Macau.

    One of the most important global health goals is to improve patient care for people who are at risk of sepsis. T2 Biosystems helps with this endeavor by offering culture-independent diagnostics to its distributor partners in Indonesia and Malaysia. The company’s footprint in the Asia Pacific region is further increased by the new distribution deal.

  • Behind the Rise: Analyzing T2 Biosystems’ (TTOO) Extended-Session Performance

    Behind the Rise: Analyzing T2 Biosystems’ (TTOO) Extended-Session Performance

    T2 Biosystems, Inc. (NASDAQ: TTOO) continued its upward trajectory during the extended-session on Monday, marking a further increase of 3.64% to reach $4.55. This follows a notable regular-session surge of 18.81%, closing at $4.39. The uptick in TTOO stock value appears to be driven by recent developments, as no direct news correlates to this scenario.

    Strategic Partnership With ECO Laboratory

    In an effort to establish a strategic partnership, T2 Biosystems (TTOO) and ECO Laboratory, a clinical laboratory accredited under the Clinical Laboratory Improvement Amendments (CLIA) and situated in Massachusetts, recently signed a non-binding letter of intent (“LOI”). Working together on this project is ECO Laboratory’s founder, Karen Weeks, who has a wealth of experience and understanding in the field of Lyme diagnostics.

    The primary focus of this collaboration is the launch of the T2Lyme Panel as a Laboratory Developed Test (LDT), aimed at early Lyme disease detection. Additionally, T2 Biosystems aims to establish a leading Lyme testing laboratory within the United States.

    Revolutionizing Lyme Disease Detection

    The T2Lyme Panel represents a groundbreaking direct-from-blood molecular diagnostic test tailored for early detection of Borrelia burgdorferi, the causative agent of Lyme disease in the United States. Lyme disease stands as the predominant vector-borne ailment in America, with approximately 3.4 million tests conducted annually.

    Presently, the diagnostic protocol relies on a two-tiered antibody test algorithm, which is only reliably effective four to eight weeks post-infection. Unchecked, the bacteria can disseminate throughout the body, complicating treatment efforts. Early Lyme disease symptoms mimic those of the flu, yet Borrelia burgdorferi infections may lead to chronic and incapacitating conditions.

    Future Outlook

    T2 Biosystems is diligently concluding internal validation and verification processes, anticipating readiness for product launch by the third quarter of 2024. This endeavor signifies a critical advancement in addressing the pressing need for highly sensitive and early Lyme disease detection, potentially mitigating the severity of its long-term impact on affected individuals.

  • What Led The TTOO Stock To Increase In Premarket Session?

    What Led The TTOO Stock To Increase In Premarket Session?

    The share price of T2 Biosystems Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, was up 3.88% in pre-market trading at $1.07. Last session, TTOO closed at $1.03, losing -0.96% or $0.01. The price of each TTOO share fluctuated from $1.00 to $1.04 during the past session. A total of 3.2 million shares of TTOO stock were traded on the day, less than the company’s average daily volume of 4.66 million over the previous 50 days and a fraction of share volume of 8.17 million for the year to date.

    TTOO’s stock has suffered a decline of 39.59% in the past 12 months, and it has fallen -4.63% in the last week. TTOO stock has declined by -43.09% over the last six months, and by -12.71% over the last three months. Since the start of this year, the stock has lost -16.94%.  Following granting of the inducement award, TTOO stock is rising.

    Who is TTOO granting the award to?

    Using T2 Biosystems’ products, clinicians are able to effectively treat their patients faster than ever before, improving patient care and reducing costs. The T2Dx Instrument, T2Candida Panel, T2Bacteria Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel available from TTOO are all powered by the T2MR (T2 Magnetic Resonance) technology. TTOO is developing future products such as the T2Cauris Panel, the T2Lyme Panel, and additional products to detect infectious pathogens that share antimicrobial resistance genes and biothreat pathogens.

    Eleven new employees received inducement awards from T2 Biosystems yesterday.

    • TTOO made the awards under its Inducement Award Plan on July 8, 2021.
    • On March 1, 2018, the program was adopted by TTOO, amended and restated on January 8, 2020.
    • Through TTOO’s Equity Incentive Program, new employees of the company are awarded equity awards.
    • As part of the inducement awards, employees received options to buy 321,000 shares of TTOO common stock, which were granted for a ten-year period.
    • On July 8, 2021, TTOO Biosystems common stock closed at $1.06 per share on the Nasdaq Capital Market, which was the exercise price of the options.
    • Over the next four years, employees’ options vest 25% on the first anniversary of their hire date, and the remainder vesting after that in equal monthly installments.

    How was the award granted?

    An independent compensation committee of the board of directors of TTOO approved the award. According to Nasdaq Marketplace Rules, the award was granted as an inducement material to entice the new employee to become employed by T2 Biosystems (TTOO).

  • Why T2 Biosystems Inc. (TTOO) is stock surging in the Pre-market hours today?

    Why T2 Biosystems Inc. (TTOO) is stock surging in the Pre-market hours today?

    A leader in the rapid detection of pathogens, causing sepsis, T2 Biosystems Inc. (NASDAQ: TTOO) stock rose 43.125% to $2.290 in the pre-market session. At the last closing, Company was up 10.34% to $1.600.

    Company Details

    T2 Biosystems is committed to optimizing patient safety and reducing healthcare costs by empowering doctors to treat patients quicker and more reliably than ever.T2 Biosystems products are powered by the patented T2 Magnetic Resonance technology and include the T2Dx Instrument, T2Candida Panel, T2Bacteria T2Resistance Panel, and T2SARS CoV-2 Panel. Besides additional drugs for the identification of bacterial and fungal pathogens and related antimicrobial resistance markers, and biothreat pathogens, T2 Biosystems has an active pipeline of potential products, including the T2Cauris Panel and T2Lyme Panel.

    Recent News and Development:

    On January 11, 2021, the Company announced that its T2SARS-CoV-2 Panel could detect multiple variants of the T2SARS-CoV-2 virus responsible for COVID-19 infections recently identified in the United Kingdom, South Africa, and the United States.

    With the emergence of multiple strains of the COVID-19 virus, it is essential to continue to provide a diagnostic solution during this ongoing pandemic, said John Sperzel, CEO of T2 Biosystems.

    After extensive analysis, we can confidently say that our T2SARS-CoV-2 Panel can continue to save lives by detecting multiple variants of the SARS-CoV-2 virus, demonstrating clinical sensitivity of over 95 specificities of over 100 percent.

    The variants identified in South Africa (B.1.351) and United Kingdom (B.1.1.7) share many mutations, mirrored mainly in the S gene, which encodes the spike protein.

    SUMMARY

    We’re living through the “golden age” of biotechnology, according to some experts. Science is opening new doors to the treatment and prevention of diseases previously unimaginable. Biotech stocks offer the possibility of huge returns for investors during this golden age.